Introduction
Astrocytomas are the most common primary central nervous system (CNS) tumors in adults, accounting for 4 ± 5% of all cancer related deaths (20 000 deaths/year in N America (Mahaley et al., 1989) . These tumors arising from the astrocyte (a supportive glial cell of the CNS) are classi®ed by the World Health Organization into four increasing grades of malignancy (Kleihues et al., 1991) . Grade 3 and Grade 4 astrocytomas (glioblastoma=GBM), which are also termed malignant astrocytomas collectively, are the most common subtype in adults and were the source of the four cell lines used in this study. Despite technical improvements in neurodiagnostic and neurosurgical capabilities, survival of patients diagnosed with malignant astrocytomas have not signi®cantly improved, with 18 and 9 month mean survival rates for Grade 3 and Grade 4 astrocytomas, respectively (Mahaley et al., 1989) .
Human malignant astrocytomas overexpress many growth factors and their cognate receptors, of which several are functionally relevant to the growth of these tumor cells. For example, PDGF and PDGFRs are expressed at high levels without gene ampli®cation by malignant astrocytoma cell lines and tissue (Guha et al., 1995a,b; Hermanson et al., 1992; NisteÂ r et al., 1991) , suggesting autocrine/paracrine stimulation. Breaking the PDGF stimulatory loop with PDGF dominant negative mutants (Shamah et al., 1993) or PDGFR activation inhibitors (Kovalenko et al., 1994) , decreases the proliferation of malignant astrocytomas in culture and in animal models. EGFR ampli®cation is associated with approximately 50% of the most malignant Grade 4 astrocytomas (GBM) (Libermann et al., 1985; Olson et al., 1994; Steck et al., 1988; Wong et al., 1987) , and about 40% of these tumors express a truncated EGFR (Ekstrand et al., 1995 (Ekstrand et al., , 1994 Nishikawa et al., 1994; Olson et al., 1994) missing a large portion of the extracellular ligand binding domain, along with wild type EGFR. This truncated EGFR fails to bind EGF or TGF-a, and is constitutively activated. It is expressed in the actual tumors or xenograft animal models, but not in the derived astrocytoma cell lines, and provides a speci®c growth advantage in vivo (Ekstrand et al., 1994; Nishikawa et al., 1994) . Other growth factors which are potentially relevant to the proliferation of human astrocytomas include vascular endothelial growth factor (VEGF) (Millau et al., 1994; Plate et al., 1993 Plate et al., , 1992 Windel et al., 1994) , ®broblastic growth factor (Libermann et al., 1987; Morrison, 1991; Paulus et al., 1990; Takahashi et al., 1990) and insulin derived growth factor (Antoniades et al., 1992; Glick et al., 1992; Prisell et al., 1987; Sandberg-Nordqvist et al., 1993; Trojan et al., 1993) . Therefore in summary, activation of these RTKs by autocrine or paracrine stimulation, or as a consequence of mutations, is postulated to contribute to the growth of astrocytomas.
The Ras-Raf-MAP kinase mitogenic signaling pathway is pivotal in transducing signals from many RTKs including PDGFRs and the EGFR (Mulcahy et al., 1985; Muroy et al., 1992; Qui and Green, 1991; Satoh et al., 1990a,b; Satoh and Caziro, 1992) . Oncogenic mutations of Ras, found in approximately 30% of all human cancers, have not been detected in human malignant astrocytomas (Bos, 1989) . However, we demonstrate in this study that levels of Ras.GTP in human malignant astrocytoma cells are similar to those found in ®broblasts transformed by an oncogenic Ras variant. Furthermore, using a recently described enzymatic assay, we demonstrate elevated levels of Ras activity in human malignant astrocytoma specimens. We hypothesize that elevated Ras.GTP levels in human malignant astrocytoma cells result from proliferative signals emanating from RTKs such as the PDGFRs and EGFR, which are highly expressed in these tumor cells. In support of this hypothesis, we demonstrate that several protein-protein interactions involved in transducing signals from activated RTKs to activate Ras are present in the malignant astrocytoma cells. The mammalian Son of Sevenless protein family (mSos), which are guanine-nucleotide exchange factors, convert Ras.GDP bound to the inner cell membrane to Ras.GTP (Aronheim et al., 1994; Bon®ni et al., 1992; Rogge et al., 1991; Simon et al., 1991) . mSos is associated through its proline rich C-terminal tail with the SH3 domains of Grb2, which binds phosphotyrosine (P-Tyr) residues on activated RTKs through its SH2 domain (Arvidsson et al., 1994; Batzer et al., 1994; Buday and Downward, 1993; Egan et al., 1993; Li et al., 1993; Lowenstein et al., 1992; McCormick, 1993; Olivier et al., 1993; Pawson and Gish, 1992; Rozakis-Adcock et al., 1993; Simon et al., 1991; Suen et al., 1993) . In addition, the Grb2:mSos complex can also bind through the Grb2 SH2 domain to the major tyrosine phosphorylation site (Tyr 317) of Shc, another SH2 domain containing adaptor protein (McCormick et al., 1993; Pelicci et al., 1992; Rozakis-Adcock et al., 1993 Salcini et al., 1994; Skolnik et al., 1993) . Shc can bind to activated RTKs through its C-terminal SH2 domain (Basu et al., 1994; Batzer et al., 1994; Giorgetti et al., 1994; Pelicci et al., 1995 Pelicci et al., , 1992 Pronk et al., 1994; Segatto et al., 1993; Skolnik et al., 1993; Yokote et al., 1994) , or its N-terminal phosphotyrosine binding (PTB) domain (Kavanaugh et al., 1995; van der Geer et al., 1995; van der Geer et al., 1996) . The interactions of the Grb2:mSos complex with activated receptors or phosphorylated Shc are important in activation of the Ras pathway. In addition to demonstrating that RTKs expressed by the human malignant astrocytoma cells are capable of activating the Ras-Raf-MAP kinase pathway, we also demonstrate that this pathway is important in transducing the mitogenic signals by transfection of the Ha-Ras-Asn17 dominant inhibitory mutant or by pharmacological inhibition of Ras pathway with farnesyl transferase inhibitors (FTI).
Results

Lack of oncogenic Ras mutations in human astrocytoma cell lines
Prior work has demonstrated that oncogenic activating mutations in Ras were not present in any human malignant astrocytoma tumors (Bos et al., 1989) . To rule out any cell culture induced mutations we sequenced through codon 12, 13 and 61 of Ha-and Ki-Ras in the four established astrocytoma cell lines, using RT ± PCR. Screening for mutations in these codons would encompass the overwhelming majority of activating Ras mutations in human tumors. Fluorescein labeled primers were used and sequencing undertaken with the ALF DNA sequencer. The primers used for the RT ± PCR reactions were as follows: Ha-Ras: 5' primer: ATGACGGAATA-TAAGCTGGTG and 3' primer: Flu-CTGTACTGG-TGGATGTCCTC; Ki-Ras: 5' primer: ATGACTG-AATATAAACTTGTGGT and 3' primer: Flu-ATAA-TGGTGAATATCTTCAAATG. No mutations of Haor Ki-Ras were detected in any of the cell lines, validating that human astrocytoma tumors or derived established cell lines do not harbor oncogenic activating Ras mutations.
Levels of Ras.GTP are elevated in human malignant astrocytoma cell lines and operative specimens 32 P-Ras loading experiments demonstrated that in v-Hras transformed ®broblasts (RT8 cells) approximately 30% of the total Ras was in the Ras.GTP bound state, compared to 5% for non-transformed NIH/3T3 cells ( Figure 1 ). Non-transformed normal human fetal astrocytes (Clonetics) had 11.2+1.1 %Ras.GTP/ (Ras.GDP+Ras.GTP). Although human malignant astrocytomas do not harbor oncogenic Ras mutations (Bos et al., 1989) , 20 ± 30% of the total Ras was in the GTP bound state in each of the four astrocytoma cell lines in calf serum. Thus the level of Ras.GTP in human malignant astrocytoma cell lines are similar to those found in Ras tranformed RT8 cells and elevated from normal human astrocytes.
Using an enzymatic assay, 20 human GBMs, and two non-neoplastic brain specimens (head injury) were evaluated for Ras activity. The mean amount of Ras.GTP was 1.62+0.36 femtomoles (fmoles)/mg of GBM DNA, compared to 0.08 and 0.04 fmoles/mg of non-neoplastic brain DNA (Figure 2 ). When Ras activity was expressed as percent of total Ras normalized to mg tumor protein [%Ras.GTP/(Ras.GDP+ Ras.GTP)], the value for the GBM specimens were similarly elevated at 53.5+5%, compared to 0.5 and Figure 1 32 P-Ras loading assay demonstrating elevated levels of the percent of total Ras (Ras.GDP+Ras.GTP) that is in the Ras.GTP bound state in all four human malignant astrocytoma cell lines (U373, U343, U138, U87) in calf serum. The levels of Ras.GTP in the astrocytoma cell lines, which do not have activating mutations of Ras, are similar to v-H-ras transformed RT8 ®broblasts and much higher than non-transformed NIH3T3 ®broblasts and non-transformed normal human astrocytes, in calf serum 2.3% in the non-neoplastic human brain samples (data not shown).
Expression of PDGFRs and EGFRs by human malignant astrocytoma cell lines
The clonally derived established astrocytoma cell lines were obtained from malignant (Grade 3 or Grade 4) human astrocytoma specimens, and have been previously well characterized (NisteÂ r et al., 1991) . PDGFR-a was expressed only by the U373 cells (Figure 3a) , while the other three cell lines expressed variable amounts of PDGFR-b (Figure 3b ). The U138 and U87 lines respectively expressed 4.2 and 3.3 times more PDGFR-b than did NIH3T3 cells, which contain approximately 10 5 PDGFR-b per cell (Seifert et al., 1989) . All the astrocytoma cells expressed variable amounts of EGFR (Figure 3c) , with U343 cells expressing 1.7 times the amount expressed by the HER14 cells, which are transfected ®broblasts that overexpress the human EGFR.
Interaction of EGFR expressed by the human malignant astrocytoma cell lines with activators of the Ras pathway
To investigate whether the EGFR expressed by the human astrocytoma cells interact with cytosolic signal transducing proteins capable of activating Ras, we undertook immunoprecipitation and Western blot experiments with these cell lysates. All the astrocytoma cell lines expressed the three isoforms of Shc (66, 52 and 46 kDa), with tyrosine phosphorylation of the isoforms upon EGF stimulation resulting in retarded gel electrophoretic mobility (Figure 4a ) . EGF stimulation resulted in phosphorylation of the 52 and 46 kDa Shc isoforms on tyrosine in all the cell lines; the 66 kDa Shc isoform was not detectably tyrosine phosphorylated in HER14 and U343 cells (Figure 4b ), the two cell lines with the highest levels of EGFR expression (Figure 3c ). Upon EGF stimulation and tyrosine phosphorylation, Shc was found to bind Grb2 (Figure 4c ). In EGF stimulated astrocytoma cells, with the exception of the U138 line, we detected a complex containing both Shc and the EGFR (Figure 4d ). Following PDGF stimulation (data not shown), the PDGFRs also complexed with tyrosine phosphorylated Shc, demonstrating that both the EGFR and PDGFRs expressed by human malignant astrocytoma cell lines are capable of associating with the Shc adaptor protein, and stimulating formation of a Shc-Grb2 complex.
Inhibition of Ras activation in human astrocytoma cell lines
To inhibit Ras activation, astrocytoma cells were transfected with the Ha-Ras-Asn17 dominant inhibitory mutant, under control of a dexamethasone inducible promoter . In these cells the MMTV promoter was extremely leaky, with RasAsn17 protein expression increasing by only 20% in the presence of 1 mM dexamethasone, as determined by densitometry (data not shown).
32
P-Ras loading assay and the novel enzymatic assay were used to measure levels of Ras.GTP in the U373 clones transfected with Ha-Ras-Asn17 construct in calf serum ( Figure 5a , Table 1 ). The mean percentage of total Ras in the Ras.GTP bound form in the U373 cells transfected with the empty MMTV vector was about 20%, measured in four separate experiments, Figure 5a . Using the enzymatic assay, Table 1 , which allows direct quanti®cation of Ras.GTP, the MMTV vector transfected control astrocytoma cells had 3.4 fmoles Ras.GTP/mg DNA, approaching levels found in the vras transformed RT8 cells and much higher than in non-transformed NIH3T3 cells (5.7 and 0.2 fmoles Ras.GTP/mg DNA respectively). In comparison, expression of Ha-Ras-Asn17 signi®cantly decreased levels of activated Ras.GTP in the U373 cells to a mean value of about 10%, even in the absence of dexamethasone, presumably due to leakiness of the MMTV construct, Figure 5a . With 1 mM dexamethasone induction, the level of Ras.GTP further decreased in the U373 cells to about 6%, which is similar to that found in non-transformed NIH3T3 ®broblasts ( Figure  1 ). Direct quantitative measurement of Ras.GTP in the Ha-Ras-Asn17 expressing U373 astrocytoma cells induced with 1 mM dexamethasone, also demonstrated decreased Ras.GTP levels with 0.9 fmoles Ras.GTP/mg DNA, Table 1 .
Inhibition of MAP kinase activation in human astrocytoma cells where Ras activation is blocked
Activation of MAP kinase was determined by the quantitative Myelin Basic Protein (MBP) kinase assay ( Figure 6 ) and the semiquantitative gel retardation assay based on the electrophoretic migration of Table 1 . (b) Colony formation assay and (c) proliferation assay in 10% calf serum of these transfected U373 cells, demonstrate decreased number of colonies (b) and anchorage dependent proliferation rate (c) in the U373 cells with the inhibited Ras activity due to the Ha-RasAsn17 mutant activated ERK1 (p44-MAP K), due to phosphorylation on threonine and tyrosine residues (data not shown). In serum starved conditions (EGF-), MAP kinase activity in the U373 astrocytoma cells was low and similar to serum starved Her14 cells. EGF stimulation (8610 78 M) for 5 min causes a marked rise in MAP kinase activity in the U373 cells transfected with the MMTV vector alone, which was attenuated by approximately 50% by U373 cells expressing the HaRas-Asn17 dominant inhibitory mutant. Addition of dexamethasone did not signi®cantly alter the MAP kinase activity in any of the experiments. Similar results were also obtained from the gel retardation assay (data not shown). The decreased MAP kinase activation with EGF stimulation in the Ha-Ras-Asn17 expressing astrocytoma cells, is consistent with reduced Ras.GTP levels in these cells in calf serum, Figure 5a and Table 1 .
Eect of blocking Ras activation by Ras-Asn17 on in vitro proliferation of human malignant astrocytoma cell lines
Colony formation and anchorage dependent proliferation assays, on transfected astrocytoma cells that were pooled and underwent neomycin selection, both demonstrated that the proliferation rates of the four astrocytoma cell lines were decreased by blocking Ras activation by the Ha-Ras-Asn17 dominant inhibitory mutant (data not shown). Colony formation and proliferation assays on stable cell clones shown to express Ras-Asn17 were also undertaken for all four of the astrocytoma cell lines, and gave similar results to the assays on pooled cell cultures. Decreased number of colonies was found in the U373 clone transfected with the MMTV-17 construct, compared to cells transfected with the MMTV vector only and incubated with 0 or 1 mM dexamethasone induction, Figure  5b . The proliferation assay (Figure 5c ) paralleled the colony formation assay, with a decreased proliferation rate in the Ha-Ras-Asn17 expressing astrocytoma cells, compared to those transfected with only the MMTV.
Anchorage independent soft agar assay on U87 human malignant astrocytoma cells transfected with the Ras-Asn17 inhibitory mutant also demonstrated decreased tumorigenic proliferation, Figure 7 . The number and average size of the U87 colonies with decreased Ras.GTP levels due to Ras-Asn17 expression was much reduced, compared to MMTV vector only transfected U87 cells.
Eect of blocking Ras activation by farnesyl transferase inhibitor (FTI) on human astrocytoma cells
Following 16 days of growth (12 days of 10 mM L-739,749), the mean cell count for parental U87 cells was 133 238+13 517 cells per well, while for cells treated with the vehicle (0.1% methanol) alone the mean cell count was 116 557+7532, and for cells treated with 10 mM L-739,749, the mean count was 61089+4776 (Figure 8 ). This represents a reduction in cell number of 54% and 48% when comparing L-739,749 treated U87 cells to parental U87 cells (P=0.0108 by paired t-test) and vehicle-treated cells (P=0.0063 by paired t-test) respectively, both following 12 days of drug therapy.
Discussion
Understanding and potentially inhibiting the common signal transduction pathway(s) utilized by the various activated RTKs in human malignant astrocytoma, may be of therapeutic advantage compared to inhibition of each RTK separately. For example, the protein kinase C (PKC) pathway has been implicated in astrocytoma proliferation, leading to clinical trials with PKC inhibitors in recurrent GBMs with equivocal results (Ahmad et al., 1994; Benzil et al., 1992; Misra-Press et al., 1992; Pollack et al., 1990) . There are several reasons to be interested in Ras-mediated signaling in human malignant astrocytomas expressing activated RTKs. First, the Ras-Raf-MAP kinase pathway is presently the best understood signaling pathway linking RTKs on the cell surface to the nucleus (Cantley et al., 1991; McCormick, 1993; Satoh et al., 1992 , 1990a,b) . Third, it is hypothesized that activation of Ras not only leads to tumor cell proliferation but also tumor vascularization by transcriptional upregulation of the extremely potent and speci®c angiogenic factor, VEGF (Rak et al., 1995) . Hence, activation of Ras may be relevant to the proliferation of astrocytoma cells and to tumor angiogenesis, both of which appear critical for the growth of human malignant astrocytomas, which are one of the most vascularized of human neoplasms. Another reason to examine the role of Ras signaling in astrocytomas is the development of FTI's to block Ras activation. These agents reportedly have minimal toxicity and appear ecacious in inhibiting the growth of a variety of human tumors in nude mice, though their eect on human astrocytomas has not yet been reported (Gibbs, 1991; Gibbs et al., 1994 Gibbs et al., , 1993 James et al., 1993; Kohl et al., 1993 Kohl et al., , 1994 Manne et al., 1995) . Tumors without oncogenic Ras mutations, can also be growth inhibited by FTI's suggesting that if astrocytomas are dependent on Ras signaling they may be sensitive to these agents, despite the lack of activating Ras mutations in astrocytomas.
Human astrocytomas and derived cell lines, including the ones used in this study, are known to express PDGFRs and EGFR (Figure 2) (Guha et al., 1995a,b; Hermanson et al., 1992; Libermann et al., 1985; NisteÂ r et al., 1991; Olson et al., 1994; Steck et al., 1988; Wong et al., 1987) . We demonstrate in this study that these RTKs expressed by the astrocytoma cell lines are capable of activating Ras, in a stimulation dependent manner. The adaptors Shc and Grb2, are involved in activation of the nucleotide exchange factor mSos by activated RTKs, possibly by bringing mSos in proximity to Ras.GDP at the inner Figure 8 Mean+s.e.m. of U87 parental cells, U87 cells treated with vector alone (0.1% methanol), and U87 cells treated with 10 mM L-739,749 (methanol concentration 0.1%). All cells were maintained in 10% DMEM+10% CS. 4000 cells were plated on day 0, and drug therapy began on day 4. Drug and medium were replenished every 4 days. Cell counts on day 16 demonstrate a signi®cant growth inhibition of L-739,749 on U87 cells cell membrane, thereby converting it to Ras.GTP (Aronheim et al., 1994; Arvidsson et al., 1994; Basu et al., 1994; Batzer et al., 1994; Bon®ni et al., 1992; Egan et al., 1993; Lowenstein et al., 1992; Pelicci et al., 1992; Rozakis-Adcock et al., 1993 van der Geer and Hunter, 1994; van der Geer et al., 1995; Yokote et al., 1994) , or by inducing direct mSos catalytic activation (Li et al., 1996) . Upon stimulation, both EGFR (Figure 4 ) and PDGFR (data not shown) expressed by the malignant astrocytoma cell lines, bound Shc proteins and induced tyrosine phosphorylation of the 46 and 52 kDa Shc isoforms. The larger 66 kDa Shc isoform, which is produced as a consequence of alternate RNA splicing (Migliaccio, personal communication) , was not found to be tyrosine phosphorylated in the positive control HER14 cells or the U343 astrocytoma line ( Figure  4 ). In contrast to over expression of the smaller two Shc isoforms which transform ®broblasts, over expression of the 66 kDa Shc isoform does not lead to cellular transformation, and has variable expression and tyrosine phosphorylation , Migliaccio, 1997 . Upon stimulation, the SH2 domain of Grb2 was able to bind to tyrosine phosphorylated Shc. In summary, these results demonstrate the PDGFRs and EGFR, and probably other RTKs expressed by human malignant astrocytomas, are capable of activating the Ras signaling pathway.
Levels of activated Ras.GTP were elevated in all of the four astrocytoma lines, and comparable to oncogenic Ras transformed ®broblasts (Figure 1 ), though they do not harbor oncogenic Ras mutations as determined by direct sequencing. NIH3T3 cells and commercially available non-transformed normal human astrocytes were used as negative controls, and had much lower levels of Ras.GTP. To exclude culture induced artifacts, we utilized an enzymatic assay to measure Ras.GTP and Ras.GDP levels in ash frozen tissues (Guha et al., 1996; Scheele et al., 1994) . Similar to the established cell cultures, Ras activity was markedly elevated in the GBM specimens, compared to non-neoplastic brain samples (Figure 2 ). Experiments investigating whether there is a gradient of Ras activity between Grade 1 to Grade 4 (GBM) specimens are currently underway. Expression of the Ha-Ras-Asn17 dominant inhibitory mutant decreased levels of Ras.GTP in the astrocytoma cells by approximately 50%, as measured in the U373 clone (Figure 5a ). The Ha-Ras-Asn17 substitution decreases Ras.GTP levels by destabilizing Mg 2+ binding, thereby decreasing its anity to both GTP and GDP. The anity of the Ras-Asn17 mutant towards GTP is decreased to a greater extent than GDP, hence there is a relative increase in anity towards GDP (John et al., 1993) . However, the o rate of the mutant RasAsn17 from GDP is also increased compared to wild type Ras (personal communication: L Feig and A Wittinghofer), making it valid to measure %Ras.GTP/ (Ras.GDP+Ras.GTP) levels with the 32 P-Ras loading assay, as demonstrated in Figure 5a . In addition to the 32 P-Ras loading assay, we also used the enzymatic assay which allows a direct measurement of Ras.GTP levels in terms of fmoles/mg DNA, and also demonstrated decreased levels of Ras.GTP by astrocytoma cells expressing the Ras-Asn17 mutant, Table  1 . Although having reduced anity for both GDP and GTP, the Ras-Asn17 dominant inhibitory mutant is still able to bind nucleotide exchange factors such as mSos, depleting them and preventing activation of endogenous Ras Farnsworth and Feig, 1991; Feig and Cooper, 1988; Szeberenyi et al., 1990) , thereby acting in a dominant inhibitory fashion. Decreased levels of Ras.GTP in the astrocytoma cells correlated with inhibition of the major mitogenic downstream eector of Ras, involving activation of the Ras-Raf-MAP kinase pathway (Figure 6 ). Expression of Ha-Ras-Asn17 decreased proliferation in all astrocytoma cell lines, as observed in the pooled proliferation and colony formation assays and those undertaken on the isolated U373 clone ( Figure 5 ). Anchorage independent growth of the U87 cell line (which has the most tumorigenic growth in nude mice of the four astrocytoma lines, unpublished observation), was decreased by blocking Ras activation with the Ha-Ras-Asn17 inhibitory mutant (Figure 7 ). These results demonstrate that Ras activity is elevated in human malignant astrocytomas, and activation of this signaling pathway is important for tumor cell proliferation.
Farnesylation is the most critical post-translational modi®cation step of Ras, essential for its localization to the inner cell membrane and subsequent activation by RTKs (Hancock et al., 1989; Kato et al., 1992) . Although many cellular proteins are farnesylated, FTI's have demonstrated minimal toxicity in animal models while reducing growth of a variety of human tumors, with malignant astrocytomas not yet tested (Gibbs, 1991; Gibbs et al., 1994 Gibbs et al., , 1993 James et al., 1993; Kohl et al., 1993 Kohl et al., , 1994 Manne et al., 1995; . Surprisingly, growth inhibition was independent of whether or not the tumors harbor activating oncogenic Ras mutations (Nagasu et al., 1995; Sepp-Lorenzino et al., 1995) . For example, human neurogenic sarcoma cell lines are inhibited by these drugs , though elevated levels of Ras.GTP in these cells are secondary to decreased levels of neuro®bromin, one of the two major mammalian Ras-GTPase activating proteins (Basu et al., 1992; DeClue et al., 1992) , and not due to activating mutations of Ras. Another potential area of concern regarding the ultimate ecacy of FTI's on human cancers centers upon the ability of Ki-Ras, where most of the human oncogenic Ras mutations are found, to become gerynyl-gerynylated and hence become resistant to FTI's. Although equivalent antiproliferative doses of FTI's are higher for cell lines and xenotransplanted human tumors transformed with activating Ki-Ras mutations compared to Ha-Ras transformed cells, these doses of FTI's appear to be achievable with minimal toxicity.
Our preliminary data with L-739,749, an FTI developed by Merck Research Laboratories, demonstrates that pharmacological inhibition of the Ras signaling pathway inhibits proliferation of human astrocytoma cells (Figure 8 ). Current work is directed to evaluating FTI's and other agents directed at other proteins involved in the Ras signaling pathway in human malignant astrocytomas, to determine their potential therapeutic role in this presently terminal human cancer.
Materials and methods
Cell lines and transfections
Four clonally derived established human malignant astrocytoma cell lines (U-373 and U-343Cl2:6: gift of B Westermark, Uppsala, Sweden; U-138, U-87: from American Type Culture Collection, Maryland, USA) were transfected using Lipofectin (GIBCO). The Ha-Ras-Asn17 dominant inhibitory mutant cDNA under control of the MMTV promoter (pMMTV-17: gift of R Habas-SUNY, Stony Brook, NY), was co-transfected with the neomycin resistant gene (pSV2-NEO) at 10 : 1 ratio, to allow for selection with 0.5 mg/ml of neomycin sulfate (GIBCO). The MMTV construct was leaky, as abundant and almost equivalent amounts of Ha-Ras-Asn17 expression were noted by Western blot analysis with either 0 or 1 mM dexamethasone induction (data not shown). Single stably transfected clones were selected and characterized for HaRas-Asn17 expression by Western blot analysis. Pooled colonies of transfected cells were obtained by allowing the neomycin resistant clones to coalesce (data not shown). NIH3T3 and HER14 ®broblasts served as positive controls for PDGFR and EGFR expression, respectively. RT8 ®broblasts, transformed with v-H-ras, served as positive controls for 32 P-Ras loading assays. Non-transformed normal human astrocytes harvested from 22 weeks gestation were obtained from Clonetics (San Diego, CA), for measurements of Ras.GTP levels.
Western blot analysis
The four human malignant astrocytoma cell lines and positive control cells were serum starved overnight (7) or stimulated (+) with recombinant PDGF-BB (30 ng/ ml65 min; U.B.I.) or EGF (80 nM65 min; U.B.I.), prior to lysis with phospholysis buer containing protease and phosphatase inhibitors (50 mM HEPES, pH 7.5, 150 mM NaCl, 10 mM NaPPi, 10% glycerol, 1% Triton X-100, 1 mM EGTA, 1.5 mM MgCl 2 100 mM NaF, 10 mg/ml leupeptin and aprotinin, 0.1 mM Na-orthovannadate, 0.1 mM PMSF). One mg of lysate as determined by BCA protein assay (Pierce) was immunoprecpitated overnight with a monoclonal antibody to PDGFR-a (U.B.I.), and polyclonal antibodies generated to the intracellular domains of PDGFR-b, EGFR and to Shc. The lysates were run on a 10% SDS gel (except for the Grb2 Western (Figure 4c ) which required a 12.5% SDS gel), transferred to nitrocellulose (Schleicher-Schuell) and blocked with 5% no-fat dry milk in TBS (blotto; TBS=20 mM Tris pH 7.5, 150 mM NaCl) for 1 h. The nitrocellulose was incubated with the primary antibodies in blotto for 2 h as labeled in the ®gures (anti-P-Tyr-U.B.I.; anti-Grb2-gift of J Schlessinger, New York, USA). After washing the blots, 125 I Protein-A was used for detection with overnight autoradiograms.
P-Ras loading assay
The percentage of p21-Ras bound to GTP compared to total p21-Ras (Ras.GTP+Ras.GDP) was determined by the 32 P-Ras loading assay, described previously (Serve et al., 1995) . In short, approximately 10 6 cells in a P100 mm tissue culture plate were grown in phosphate free media in calf serum with 0.5 mCi of 32 P-orthophosphate for 6 h. The cells were then lysed with 50 mM HEPES pH 7.4 1% Triton X-100, 100 mM NaCl and 5 mM MgCl 2 . The lysates were cleared by centrifugation and made up to 500 mM NaCl, 0.05% sodium deoxycholate and 0.05% SDS. Further clearing of the lysates were undertaken by incubating with protein G agarose (100 mL; Sigma) and Goat anti-Rat-IgG-Fc (10 mg; Cappel) complex, plus 200 mL of 10% charcoal (10% charcoal, 2% BSA in PBS) at 48C for 1 h. After centrifugation, the pre-cleared lysates were transferred to 10 mg of Y13-259 Ras antibody (Oncogene Science) coupled to a similar protein G agaroseGoat anti-Rat-IgG-Fc complex for overnight incubation at 48C. The agarose complex was then washed six times with 50 mM HEPES pH 7.4, 1% Triton X-100, 500 mM NaCl, 5 mM MgCl 2 and 0.005% SDS. Ras bound labeled GTP or GDP was eluted with 2 mM EDTA and 2 mM dithiothreitol (DTT) at 678C for 20 min and separated by ion-exchange thin layer chromatography (TLC) on PEI plates (Sigma) with 1 M KH 2 PO 4 (pH 3.4) as running buer. Nonradioactive GDP and GTP standards were also run on the TLC plates, and radioactivity corresponding to the location of the standards were visualized and quantitated using a phosphoimage analyzer (Molecular Dynamics). The percentage of p21-Ras bound to GTP was derived by dividing the GTP densitometry signal by the sum of GTP plus GDP.
32 P-Ras loading experiments were undertaken once for the four parental astrocytoma cell lines (Figure 1 ) and four times for the U373 clone transfected with HaRas-Asn17 (Figure 5a ), whose growth characteristics were fully characterized.
Enzymatic assay of Ras activity in GBM specimens
Twenty¯ash frozen human GBM specimens, two normal human brain specimens, and the U373 astrocytoma cells +Ha-Ras-Asn17 transfection were evaluated for Ras.GTP and Ras.GDP levels using the enzymatic assay described by us previously (Guha et al., 1996; Scheel et al, 1994) . In short, the tumor specimens or a P150 mm plate of cells were homogenized or lysed (approximately half a cryovial of tumor tissue is required) in 2.5 ml of cold Ras lysis buer (10 mM HEPES pH 7.4; 1 mM MgCl 2 ; 1 mg/ml Leupeptin and Aprotinin; 0.25 mg/ml Pepstatin A; 150 mM NaCl, 1% NP-40; 0.5 mM PMSF). From the homogenate, 15 ml was aliquoted for DNA extraction using trichloroacetic acid (TCA) precipitation, and the homogenate spun for 30 min at 10 000 g to remove nuclear and other cellular debris. The supernatent was split equally and immunoprecipitated overnight with either 3 mg of the monoclonal anti-(Ha, Ki, N) Ras antibody (Y13-259: Oncogene Science), or 3 mg of rat IgG as a negative control, with 30 mg of goat anti-rat IgG:Fc (Dako) and 30 mL of protein-G agarose beads (Calbiochem). Subsequently the agarose pellets were washed with 50 mM HEPES pH 7.4, 10 mM MgCl 2 , 500 mM NaCl, 1% Triton X-100, 0.005% SDS (68), 20 mM TrisPO 4 (63) and once with 5 mM TrisPO 4 . GTP and GDP bound to Ras were eluted in 30 ml of 5 mM TrisPO 4 , 2 mM DTT, 2 mM EDTA by heating at 1008C for 3 min and stored at 7708C.
The amount of Ras bound eluted GTP from the samples was measured using a luciferase based assay as described previously (Guha et al., 1996; Scheele et al., 1994) . In brief, 10 ml of sample or GTP standards (0.5 ± 20 fmol) were mixed with luciferase and ADP in the absence or presence of NDP kinase. The generated ATP was measured by the luciferase method subtracting the value obtained in the absence of NDP kinase. The amount of GTP in the samples was obtained from a standard curve, with the value from the rat IgG immunoprecipitated sample subtracted from the corresponding sample with Y13-259. This corrected GTP value was expressed per mg DNA and also per mg of protein obtained from the tumor. The amount of Ras bound eluted GDP from the samples was measured using nucleoside diphosphate kinase (NDP kinase, Sigma), as described previously (Guha et al., 1996; Scheele et al., 1994) , and normalized either to mg of protein or mg DNA of tumor sample. The Ras activity in the samples can be expressed either as %Ras.GTP/ (Ras.GDP+Ras.GTP) or in absolute amounts of fmoles of Ras.GTP/mg tumor DNA. The conclusions from either method is the same (Ras activity is elevated in GBM specimens compared to normal brain), however, we prefer the latter (Figure 2 ), since it accounts for heterogeneity between tumor samples, and for the amounts of cellular vs. non-cellular elements such as extracellular matrix, tumor necrosis, hemorrhage etc.
MAP kinase activity by MBP kinase assay
Cells were serum-starved for 48 h. Those cells undergoing stimulation with EGF were incubated at 378C with 8610 78 M EGF for 5 min. Cells were lysed using kinase lysis buer (25 mM HEPES pH 7.5, 0.3 M NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 20 mM b-glycerophosphate, 1% Triton X-100, 0.5 mM dithiothreitol, 20 mg/mL aprotinin, 20 mg/mL leupeptin, 1 mM phenylmethylsulfonyl¯uoride, 1 mM sodium orthovanadate). Protein concentration was determined using the bicinchoninic acid method (Pierce Chemical Company, Rockford, IL). 100 mg of protein were immunoprecipitated overnight with protein-A sepharose beads and 50 mL of anti-ERK2 antibody (Santa Cruz Biotechnology, Santa Cruz, CA), which preferentially recognizes ERK2 but also immunoprecipitates ERK1.
Immunoprecipitates were washed once with kinase lysis buer, then three times with 1% NP40 in PBS with 2 mM Na 3 VO 4 , then once with 100 mM Tris.HCl (pH 7.5) in water with 0.5 M LiCl. Lysates were ®nally washed once with kinase reaction buer (12.5 mM MOPS pH 7.5, 12.5 mM b-glycerophosphate, 7.5 mM MgCl 2 , 0.5 mM EGTA, 0.5 mM NaF, 0.5 M Na 3 VO 4 ). Following this ®nal wash, immunoprecipitates were incubated for 1 h at 308C with 50 mL kinase reaction buer supplemented with 1.5 mg/mL bovine myelin basic protein (Sigma Chemical Company, St. Louis, MO), 2 mM ATP and 10 mCi/mL [g-32 P]ATP (NEN/Dupont, Boston, MA; speci®c activity 3000 Ci/mmol). The kinase reaction was terminated by adding 25 mL of 36sample buer (187.5 mM Tris-HCl pH 6.8, 6% w/v SDS, 30% glycerol, 150 mM DTT, 0.1% w/v bromphenol blue), samples boiled for 5 min at 1008C, and loaded on a 15% SDS ± PAGE gel. Myelin Basic Protein was identi®ed as a 17 kDa protein by Coomassie blue staining, and kinase activity quanti®ed on a STORM PhosphorImager (Molecular Dynamics, Sunnyvale, CA) after exposing gels on a PhosphorImager cassette for 2 h.
Proliferation assays
Colony formation assays were undertaken on stably derived clones, as demonstrated by the U373 cell line in Figure 5b . 10 6 cells were plated on 100 mm plates in DMEM media containing 10% calf serum, 0.5 mg/ml neomycin sulfate, 0 or 1 mM dexamethasone, with the media being changed every 3 days. At 1 week the plates were ®xed with absolute methanol and viable clones visualized by staining with 0.625% cresyl-violet. Pooled colony formation (data not shown) assays were also undertaken for all the four human malignant astrocytoma cell lines transfected with the MMTV-Asn17 or MMTV vector construct only.
Anchorage dependent proliferation assays of stably derived clones ( Figure 5c ) were obtained by plating 2610 3 cells in each 24 well plate containing 10% calf serum plus 0.5 mg/ml neomycin, with the number of cells counted every second day for 12 days with a Coulter Counter (Coulter Electronics Inc.). For each cell line three wells were plated and the average taken. Similar proliferation assays on pooled clones (data not shown) were also undertaken.
Anchorage-independent growth was determined in a soft agar and methylcellulose assay in 6-well plates (Figure 7) . A 3 mL soft agar feeder layer was plated in each well, consisting of 0.9% agar, 16Dulbecco's Modi®ed Eagle Medium (DMEM), and 10% calf serum. Following solidi®cation of the agar feeder layer, 3 mL of a plating layer was plated over the feeder layer. The plating layer consisted of 2.5610 4 cells diluted in 0.75% methylcellulose, 16DMEM, and 10% calf serum. Medium (16DMEM and 10% calf serum in 0.75% methylcellulose) was replenished every week. Colonies were allowed to form over a 4 week period, after which the colonies were photographed at 106 and 406 magni®cation using an inverted microscope.
Ras activity inhibition by FTI
The FTI L-739,749 was obtained from Merck Research Laboratories (gift of Allen Oli, Merck Research Laboratories, West Point, PA). The drug was stored in a 10 mM stock solution in 50% methanol at 7208C. U87 astrocytoma cells were plated in 24-well Falcon tissue culture wells (Becton Dickinson, Lincoln Park, NJ) at a density of 4000 cells per well. Cells were maintained in Dulbecco's Modi®ed Eagle Medium (DMEM) with 10% calf serum (CS) for 4 days. Medium was changed on day 4, with one set of duplicate wells being maintained in DMEM+10% CS, a second set of duplicate wells maintained in DMEM+10% CS+0.1% methanol (the vehicle alone), and a third set of duplicate wells maintained in DMEM+10% CS+10 mM L-739,749+0.1% methanol (Figure 8 ). Medium was changed and drug replenished every 4 days. Cell counts were obtained at 2 ± 4 day intervals, using a Coulter Counter model ZM (Coulter Electronics Ltd., England).
